China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
LONDON - GSK plc (LSE/NYSE:GSK) announced Thursday that its subsidiary TESARO, Inc. has filed a lawsuit against AnaptysBio, Inc. in the Delaware Chancery Court over a dispute concerning the cancer treatment Jemperli (dostarlimab).
The litigation claims that AnaptysBio has materially breached their existing license agreement for dostarlimab. According to the press release, TESARO is seeking to terminate the current agreement, obtain a perpetual license to the drug, and reduce royalties and milestone payments to AnaptysBio by 50%.
The legal action follows allegations from AnaptysBio that TESARO failed to fulfill certain requirements under their March 2014 license agreement. AnaptysBio reportedly intends to revoke TESARO’s license for dostarlimab, claims that GSK and TESARO describe as "entirely without merit."
Jemperli is currently approved in over 35 countries for treating certain endometrial cancers, which GSK notes is the most common gynecologic cancer in the United States. The company reports that the drug has shown significant growth driven by label expansions in endometrial cancer in both the U.S. and EU markets.
GSK is currently conducting clinical trials to evaluate dostarlimab’s potential use in additional cancer types, including rectal, colon, and head and neck cancers.
The company did not disclose specific details about the alleged breaches by AnaptysBio or provide a timeline for the legal proceedings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.